Two-time Grand Slam champion Simona Halep has been charged with a second drug-related offense over “inaccuracies in her passport related to athletes”.
The Romanian, 31, has been suspended since October after testing positive for a banned substance at the US Open.
His additional salary is different from what he is already stopped because.
The athlete passport program collects and compares biological data to check for discrepancies over time that indicate possible doping.
World No. 1 Halep was suspended last year after testing positive for roxadustat, an anti-anaemia drug that helps the body produce red blood cells.
The International Tennis Integrity Agency (ITIA), which oversees testing within the sport, said it would try to resolve the latest incident, but did not say how long it would take.
Nicole Sapstead, ITIA’s chief executive of anti-doping, said: “We understand that today’s announcement adds to the already complex situation.
“From the beginning of this process – and every other at ITIA – we have been committed to dealing with Ms Halep in a compassionate, efficient and timely manner.”
Halep, the 2019 Wimbledon champion, said last October that “cheating never happened” in her mind and attributed the failed test to a “bad” addition.
In April, Halep spoke first since he was suspended, he says he was frustrated by the time it took to resolve the case but ITIA said “the process is ongoing”.
The investigation of failed tests with ITIA is often difficult, especially when the player refuses to take the drug knowingly.
It is not uncommon for these cases to take several months to resolve.
In such cases, the player can produce evidence against or explain the failed test, which Halep he said he did.
This will lead to further investigation and testing by ITIA, which will allow the project to continue.
Halep, who was ranked ninth when the ban took effect, is one of the most high-profile tennis players to fail a drug test, and the most high-profile since Russian great Maria Sharapova was banned in 2016.